Stay updated with breaking news from Precigen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of $75.0 million of its common stock. In...
Precigen, Inc. presented pipeline and corporate updates at the 41st Annual J.P. Morgan Healthcare Conference. PRGN-2012 AdenoVerse™ Immunotherapy in RRP. Overview: PRGN-2012 is an investigational... | January 12, 2023
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...
– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – – PRGN-3006...
– Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference, to showcase complete...